Interesting article | PGEN Message Board Posts

PGEN   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  51791 of 52656  at  11/7/2022 11:15:36 AM  by


Interesting article


When Beam was slapped with a clinical hold for its base-edited Car-T project BEAM-201, some harboured hopes that Verve’s VERVE-101, which uses the same technology, would escape this fate. For one, BEAM-201 involves multiple edits, while VERVE-101 makes a single base change. However, investors who kept the faith were punished today by an FDA hold on VERVE-101’s IND application; the move raises the question of whether the regulator is cautious about base editing in particular, or in vivo gene editing in general. Without knowing details of the agency’s concerns, it is hard to say. Some groups have managed to get in vivo projects into US trials, including Excision Biotherapeutics, whose EBT-101 uses Crispr to make multiple cuts in the HIV genome. Intellia, however, which reported more data over the weekend on its amyloidosis contender NTLA-2001, has so far only trialled its in vivo assets outside the US. One mark against Verve is that various, more conventional anti-PCSK9 therapies are available, and the FDA has recommended that gene editing therapies be reserved for patients with no other options. The Heart-1 study of VERVE-101 continues outside the US, but Verve’s stock sank 19% this morning.

To read Evaluate Vantage’s report into next-generation genetic medicines, including more information on Verve and Excision, click here.

Status of selected gene edited projects
VERVE-101Verve TherapeuticsIn vivo base editing project targeting PCSK9 for high cholesterolPh1 Heart-1 enrolling in NZ & UK; US IND on clinical hold
BEAM-201Beam TherapeuticsEx vivo base edited Car-T for leukaemia/ lymphomaUS IND on clinical hold; Beam has submitted response to FDA
NTLA-2001Intellia Therapeutics/RegeneronIn vivo Crispr editing project targeting TTR for amyloidosisPh1 enrolling in NZ, Sweden, UK; data reported
NTLA-2002Intellia TherapeuticsIn vivo Crispr editing project targeting KLKB1 for HAEPh1/2 enrolling in Netherlands, NZ, UK; data reported
EDIT-101Editas MedicineIn vivo Crispr editing project targeting CEP290 for LCA10IND cleared 2018; in ph1/2 Brilliance; disappointing data reported
EBT-101Excision BiotherapeuticsIn vivo Crispr therapy for HIVIND cleared 2021; ph1 (NCT05144386) recruiting
Source: Evaluate Pharma &

     e-mail to a friend      printer-friendly     add to library      
Recs: 0  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Financial Market Data provided by